Packness, Esben
Davidsson, Olafur Birgir
Rostgaard, Klaus http://orcid.org/0000-0001-6220-9414
Andersen, Michael Asger
Rotbain, Emelie Curovic http://orcid.org/0000-0002-4199-772X
Niemann, Carsten Utoft http://orcid.org/0000-0001-9880-5242
Brieghel, Christian http://orcid.org/0000-0002-1816-8106
Hjalgrim, Henrik http://orcid.org/0000-0002-4436-6798
Funding for this research was provided by:
Novo Nordisk Fonden
Article History
Received: 29 September 2023
Revised: 29 July 2024
Accepted: 1 August 2024
First Online: 22 August 2024
Competing interests
: CB has received honoraria from AstraZeneca and Octapharma outside this study. ECR received consultancy fees or travel grants from Abbvie, Janssen, and AstraZeneca. CUN has received research funding and/or consultancy fees from: Abbvie, AstraZeneca, Janssen, Genmab, Beigene, Octapharma, CSL Behring, Takeda, and Eli Lilly. Other co-authors declare no competing financial interest.
: This project was recorded in the Danish Cancer Society’s register of research activities (2021-CDRC-0033). According to Danish regulations, ethics approval and informed consent are not required for studies using only register data.